Intercept Pharmaceuticals CEO and leadership

Linda Richardson serves as the Chief Commercial Officer. Prior to her appointment to this role in February 2021, she served as Senior Vice President and Head of the Cholestasis Program since joining Intercept in 2018. Ms. Richardson has more than 30 years of commercial strategy, sales and marketing experience. Prior to joining Intercept, Ms. Richardson served as Chief Strategy and Commercial Officer at Chimerix, Inc., where she oversaw marketing, market access and reimbursement, market research and analytics, forecasting, supply chain and distribution strategies, commercial operations, product communications and sales. From 2008 to 2013, Ms. Richardson held commercial leadership roles of increasing responsibility at Sanofi, where she led the company’s global GLP-1 diabetes franchise. Prior to joining Sanofi, Ms. Richardson held roles of increasing responsibility at both Reliant Pharmaceuticals and GlaxoSmithKline. Ms. Richardson has been recognized by PM360 as an “ELITE 100” award winner in the pharmaceutical industry, by the Healthcare Businesswomen’s Association as a “Rising Star,” and by PharmaVOICE as one of its “Top 100 Most Inspiring People in Life Sciences.” Ms. Richardson holds a bachelor’s degree in English from the University of Pennsylvania.

Rocco Venezia is a Chief Accounting Officer and Acting CFO at INTERCEPT PHARMACEUTICALS, INC. and is based in New York, New York. He has worked as Senior Associate at Arthur Andersen LLP; Assistant Corporate Controller at IKARIA, Inc. - now a part of Mallinckrodt Pharmaceuticals.; and Senior Manager, Department of Professional Practice at KPMG. Rocco attended Kean University. between 1995 and 1998.

Andrew Saik has over 20 years of accounting, finance, general management experience in domestic and international companies that are publicly-held and privately-owned. As the Chief Financial Officer at Auxilium Pharmaceuticals Andrew was responsible for all financial and IT functions within the company. In previous positions Andrew has been responsible for treasury, internal and external reporting, FP&A, M&A, manufacturing, strategic planning, and managed care. During his career Andrew successfully completed over 40 M&A transactions and actively lead or participated in all aspects including due diligence, negotiation, preparations of board materials, and integration planning and execution. Andrew has been a leading change agent in businesses that have changed many times over the course of his career. An accomplished CFO and exceptional leader, Andrews diverse background includes the following industries: specialty pharmaceuticals; biotech/R&D; oil and gas; banking. He is highly regarded as a mentor and “change agent”, and has built his reputation on a commitment to team building and ability to remain calm in the most challenging situations. During his career Andrew has had the opportunity to run groups outside the normal finance area which only add to his operational experience. These groups include managed care, generics, and technical operations which included four manufacturing facilities and over 1000 employees. Specialties:Business Process Improvement; Financial & Operational Turnarounds; Enhanced Cash Flow Management; SOx 404 Implementation; M&A; Business Valuations & Due Diligence; Systems Implementations

Bryan Ball serves as the Chief Quality Officer. Prior to joining Intercept, Mr. Ball was Chief Quality Officer of Immunomedics, Inc., where he was responsible for all aspects of Quality for product development, clinical trials, manufacturing, testing and distribution of the company’s clinical stage candidates and first commercial product. Mr. Ball has served in management positions at several companies, including as Senior Vice President, Quality, Environmental Health and Safety at Mallinckrodt Pharmaceuticals and Vice President positions in the Quality departments of Ikaria, Inc. and Boehringer Ingelheim. Mr. Ball holds an M.B.A from Westminster College, a M.Sc. in cell biology from University of North Carolina, Charlotte, and a B.Sc. in biology from Central Michigan University.

David Ford is a Chief Human Resources Officer at INTERCEPT PHARMACEUTICALS, INC.. He has worked as VP:Human Resources at Sanofi-Genzyme BioVentures and VP:Human Resources at SANOFI. David attended Fontainebleau.